Clients

Paratek Pharmaceuticals

Company Snapshot: Paratek Pharmaceuticals

PRTK
Last Change Volume High Low

Company Overview

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.

Client News

  1. Feb 14 2019 Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  2. Feb 13 2019 Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
  3. Feb 6 2019 New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
  4. Feb 5 2019 Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States